According to @WhiteHouse, President Biden signed an Executive Order on May 6, 2025, ending all current and future federal funding for dangerous gain-of-function research in countries of concern, aiming to enhance safety in U.S. biological research without hindering innovation (source: @WhiteHouse, May 6, 2025). For traders, this action is likely to create volatility in biotech stocks, particularly those with international exposure, and may increase interest in blockchain-based biotech solutions as regulatory scrutiny intensifies. The announcement could drive capital flow into decentralized health data platforms and related crypto assets, as investors seek alternatives less impacted by U.S. policy shifts.